Akorn-Strides JV sells ANDAs to Pfizer
This article was originally published in Scrip
Executive Summary
Akorn-Strides, the generics-focused joint venture between Akorn of the US and Strides Arcolab of India, is to sell 16 abbreviated new drug approvals (ANDAs) and 6 filed ANDAs to Pfizer for around $63 million.